Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
“With no specific treatment currently available, CI patients are currently having to deal with their condition with minimal support.
- “With no specific treatment currently available, CI patients are currently having to deal with their condition with minimal support.
- I hope that the data and insights presented today can help provide new knowledge and support for this patient community.”
In January 2024, LEO Pharma finalized the acquisition of Timber Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. - Upon completion, the Timber Pharmaceuticals lead investigational product candidate, TMB-001, was added to LEO Pharma’s pipeline.
- TMB-001 is under investigation and has not been evaluated by any health authority.